Tumor antigens discovery: Perspectives for cancer therapy

Molecular Medicine

Volumn 3, Issue 11, 1997, Pages 716-731

  Wang, Rong Fu ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE; DIFFERENTIATION ANTIGEN; GLYCOPROTEIN GP 100; HLA ANTIGEN; INTERLEUKIN 2; MONOPHENOL MONOOXYGENASE; TUMOR ANTIGEN; TUMOR SPECIFIC SHARED ANTIGEN; TUMOR SPECIFIC UNIQUE ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN PURIFICATION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN ISOLATION; REVIEW; TUMOR REGRESSION;

EID: 0031472411     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401710     Document Type: Review

References (104)

1. Rosenberg SA, Spiess P, Lafreniere R. (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321.
2. Kast WM, Offringa R, Peters PJ, Voordouw AC, Meloen RH, Van der Eb AJ, Melief CJM. (1989) Eradication of adenovirus E1-induced tumors by E1A specific cytotoxic T lymphocytes. Cell 59: 603-614.
3. Greenberg PD. (1991) Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49: 281-355.
4. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE. (1988) Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 319: 1676-1680.
5. Rosenberg SA. (1992) The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10: 180-199.
6. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethië B, Coulie P, Boon T. (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178: 489-495.
7. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen ED, Lurquin C, Szikora J-P, Reauld J-C, Boon T. (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180: 35-42.
8. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, DePlaen E, Van Den Eynde B, Knuth A, Boon T. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
9. Gaugler B, Van Den Eynde B, Van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T. (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179: 921-930.
10. Van Den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182: 689-698.
11. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, Van der Bruggen P. (1995) BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2: 167-175.
12. Robbins PF, El-Gamil M, Kawakami Y, Stevens E, Yannelli J, Rosenberg SA. (1994) Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54: 3124-3126.
13. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. (1995) Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181: 799-804.
14. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer Zum Buschenfelde K-H, Beach D. (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284.
15. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA. (1996) A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183: 1185-1192.
16. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. (1996) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184: 2207-2216.
17. Mandelbolm O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L. (1994) CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369: 67-71.
18. Blake J, Johnston JV, Hellstrom KE, Marqardt H, Chen L. (1996) Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes. J. Exp. Med. 184: 121-130.
19. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W. (1995) Immunity to oncogenic proteins. Immunol. Rev. 145: 33-59.
20. Fisk B, Blevins TL, Wharton JT, Ioannides CG. (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumorspecific cytotoxic T lymphocyte lines. J. Exp. Med. 181: 2109-2117.
21. Jung S, Schluesener HJ. (1991) Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J. Exp. Med. 173: 273-276.
22. Skipper J, Stauss HJ. (1993) Identification of two cytotoxic T lymphocyte-recognized epitopes in the ras protein. J. Exp. Med. 177: 1493-1498.
23. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, Sette A, Serra HM. (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. U.S.A. 91: 2105-2109.
24. Rammensee HG, Friede T, Stevanoviic S. (1995) MHC ligands and peptide motifs: First listing. Immunogenetics 41: 178-228.
25. Bouchard B, Fuller BB, Vijayasaradhi S, Houghton AN. (1989) Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J. Exp. Med. 169: 2029-2042.
26. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer Zum Buschenfelde K-H, Boon T. (1994) Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24: 759-764.
27. Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wolfel T, Boon T, Lethe B. (1996) A tyrosinase nonpeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur. J. Immunol. 26: 224-230.
28. Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL, Boon T, Hunt D. (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183: 527-534.
29. + T lymphocytes. J. Interferon Cytokine Res. 15: 739-746.
30. + T lymphocytes infiltrating human breast cancer recognize autologous tumor in an MHC-class II restricted fashion. Cancer Immunol. Immunother. 40: 1-9.
31. + T cells specifically recognize a shared melanomaassociated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. U.S.A. 91: 9461-9465.
32. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr-transformed B cells. Int. J. Cancer 58: 69-79.
33. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183: 1965-1971.
34. + T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J. Immunol. 154: 772-779.
35. Kawakami Y, Eliyahu S, Delgaldo CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA. (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. U.S.A. 91: 3515-3519.
36. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JB, Appella E, Rosenberg SA. (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med. 180: 347-352.
37. Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini L, Farina C, Nicolini G, Wolfel T, Brichard V, Boon T, Bordignon C, Anichini A, Parmiani G. (1995) Cytotoxic T lymphocyte clones from different patients display limited T-cell receptors variable gene usage in HLA-A2 restricted recognition of Melan/Mart-1 melanoma antigen. Proc. Natl. Acad. Sci. U.S.A. 92: 5674-78.
38. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154: 3961-3968.
39. Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG. (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanocyte-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179: 1005-1009.
40. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. (1994) Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. U.S.A. 91: 6458-6462.
41. Adema GJ, de Boer AJ, van't Hullenaar R, Denijn M, Ruiter DJ, Vogel AM, Figdor CG. (1993) Melanocyte lineage-specific antigens recognized by monoclonal antibodies NK1-bete, HMB-50, and HMB-45 are encoded by a single cDNA. Am. J. Pathol. 143: 1579-1585.
42. Bakker A, Schreurs M, Tafazzul G, de Boer A, Kawakami Y, Adema G, Figdor C. (1995) Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int. J. Cancer 62: 97-102.
43. Skipper JCA, Kittlesen DJ, Hendrickson RA, Deacon DD, Harthun NL, Wagner SN, Hunt DF, Engelhard VH, Slingluff CL. (1996) Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J. Immunol. 157: 5027-5033.
44. Cox AL, Skipper J, Cehn Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL. (1994) Identification of a peptide recognized by five melanomaspecific human cytotoxic T cell lines. Science 264: 716-719.
45. Topalian S, Solomon D, Avis FP, Chang AE, Freeksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA. (1988) Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J. Clin. Oncol. 6: 839-853.
46. Mattes MJ, Thomson TM, Old LJ, Lloyd KO. (1983) A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int. J. Cancer 32: 717-721.
47. Thomson TM, Real FX, Murakami S, Cordon-Cardo C, Old LJ, Houghton AN. (1988) Differentiation antigens of melanocytes and melanoma: Analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J. Invest. Dermatol. 90: 459-466.
48. Thomson TM, Mattes JM, Roux L, Old LJ, Lloyd KO. (1985) Pigmentation-associated glycoprotein of human melanoma and melanocytes: Definition with a mouse monoclonal antibody. J. Invest. Dermatol. 85: 169-174.
49. Jimenez-Cervantes C, Solano F, Kobayashi T, Urabe K, Hearing VJ, Lozano JA, Garcia-Borron JC. (1994) A new enzymatic function in the melanogenic pathway. J. Biol. Chem. 269: 17993-18001.
50. Falk K, Rotzschke O, Takiguchi M, Grahovae B, Gnau V, Stevanovic S, Jung G, Rammensee H-G. (1994) Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules. Immunogenetics 40: 238-241.
51. Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA. (1996) Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183: 1131-1140.
52. Shaw MW, Choppin PW, Lamb RA. (1983) A previously unrecognized influenza B virus glycoprotein from a bicistronic mRNA that also encodes the viral neuraminidase. Proc. Natl. Acad. Sci. U.S.A. 80: 4879-4883.
53. Spiropoulou CF, Nichol ST. (1993) A small, highly basic protein is encoded in overlapping frame within the P gene of vesicular stomatitis virus. J. Virol. 67: 3103-3110.
54. Schwartz S, Felber BK, Pavlakis GN. (1992) Mechanism of translation of monocistronic and multicistronic human immunodeficiency virus type 1 mRNAs. Mol. Cell. Biol. 12: 207-219.
55. Serrano M, Hannon GJ, Beach D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 [see comments]. Nature 366: 704-707.
56. Sherr CJ, Roberts JM. (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9: 1149-1163.
57. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000.
58. Malarkannan S, Afkarian M, Shastri N. (1995) A rare cryptic translation product is presented by Kb major histocompatibility complex class I molecule to alloreactive T cells. J. Exp. Med. 182: 1739-1750.
59. Robbins P, El-Gamil M, Li YF, Fitzgerald E, Kawakami Y, Rosenberg SA. (1997) The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J. Immunol. 159: 303-308.
60. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, El-Gamil M, Rosenberg SA, Yang JC. (1997) Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185: 453-460.
61. Sidney J, Grey HM, Kubo RT, Sette A. (1996) Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol. Today 17: 261-266.
62. Wang R, Johnston S, Southwood S, Sette A, Rosenberg SA. (1997) Recognition of an antigenic peptide derived from TRP-2 by cytotoxic T lymphocytes in the context of HLA-A31 and -A33. J. Immunol. In press.
63. Traversari C, Van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T. (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176: 1453-1457.
64. Van der Bruggen P, Szikora J-P, Boel P, Wildmann C, Somville M, Sensi M, Boon T. (1994) Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing Cw1601. Eur. J. Immunol. 24: 2134-2140.
65. Van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, de Smet C, Traversari C, Townsend A, Boon T. (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24: 3038-3043.
66. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. U.S.A. 94: 1914-1918.
67. Van Elsas A, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJ, Schrier PI. (1995) Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int. J. Cancer 61: 389-396.
68. Houbiers JGA, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJH, Brand A, Momburg F, Kast WM, Melief CJM. (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23: 2072-2077.
69. Nijman HW, van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ. (1994) p53, a potential target for tumordirected T cells. Immunol. Lett. 40: 171-178.
70. Nijman HW, Houbiers JGA, van der Burg SH, Vierboom MPM, Kenemans P, Kast WM, Melief CJM. (1993) Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: Relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. Immunotherapy 14: 121-126.
71. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. (1995) Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. U.S.A. 92: 11993-11997.
72. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T. (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. U.S.A. 92: 7976-7980.
73. Grunwald GB. (1993) The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. Curr. Opin. Cell. Biol. 5: 797-805.
74. Hoschuetzky H, Aberle H, Kemler R. (1994) β-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J. Cell. Biol. 127: 1375-1380.
75. Becker K-F, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hofler H. (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 54: 3845-3852.
76. Kawanishi J, Kato J, Sasaki K, Fujii S, Watanabe N, Niitsu Y. (1995) Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the β-catenin gene in a human cancer cell line, HSC-39. Mol. Cell. Biol. 15: 1175-1181.
77. Korinek V, Baker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science 275: 1784-1787.
78. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in betacatenin or APC. Science 275: 1787-1790.
79. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275: 1790-1792.
80. Brandle D, Brasseur F, Weynants P, Boon T, Van Den Eynde B. (1996) A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183: 2501-2508.
81. Robbins PF, El-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA. (1995) Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24 restricted tumor-infiltrating lymphocytes. J. Immunol. 154: 5944-5950.
82. Ioannides CG, Fisk B, Pollack MS, Frazier ML, Wharton JT, Freedman RS. (1993) Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on nonovarian tumour clones. Scand. J. Immunol. 37: 413-424.
83. Yoshino I, Peoples GE, Geoedegebauure PS, Mazizrz R, Eberlein TJ. (1994) Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J. Immunol. 152: 2393-2400.
84. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA. (1994) Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54: 16-20.
85. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-deroed peptide. Proc. Natl. Acad. Sci. U.S.A. 92: 432-436.
86. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ. (1995) Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J. Immunol. 155: 4486-4491.
87. Ionaaides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. (1993) Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151: 3693-3703.
88. Magadan-Blander J, Domenech N, Finn OJ. (1993) Specific and effective T-cell recognition of cells transfected with a truncated human mucin cDNA. Ann. N.Y. Acad. Sci. 690: 231-243.
89. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magadan-Blander J, Barratt-Boyes SM. (1995) MUC-i epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145: 61-89.
90. Houghton AN. (1994) Commentary: Cancer antigens: Immune recognition of self and alterted self. J. Exp. Med. 180: 1-4.
91. Nanda NK, Sercarz EE. (1995) Induction of anti-self-immunity to cure cancer. Cell 82: 13-17.
92. Nordlund JJ, Kirkwood M, Forget BM, Milton G, Albert DM, Lerner AB. (1983) Vitiligo in patients with metastatic melanoma: A good prognostic sign. J. Am. Acad. Dermatol. 9: 689-695.
93. Bystryn J-C, Rigel D, Friedman RJ, Kopf A. (1987) Prognostic significance of hypopigmentation in malignant melanoma. Arch. Dermatol. 123: 1053-1055.
94. Richards JM, Mehta N, Ramming K, Skosey P. (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J. Clin. Oncol. 10: 1338-1343.
95. Visseren MJ, Van Elsas A, van der Voort EI, Ressing ME, Kast WM, Schrier PI, Melief CJ. (1995) CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol. 154: 3991-3998.
96. Hara I, Takechi Y, Houghton AN. (1995) Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the Brown locus protein. J. Exp. Med. 182: 1609-1614.
97. Young JW, Inaba K. (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183: 7-11.
98. Henderson RA, Nimgaonkar MT, Watkins SC, Robbins PD, Ball ED, Finn OJ. (1996) Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res. 56: 3763-3770.
99. Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P. (1996) Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 56: 5672-5677.
100. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP. (1995) IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154: 5282-5292.
101. Irvine K, Rao J, Rosenberg S, Restifo N. (1995) Cytokine enhancement of DNA immunization leads to treatment of established pulmonary metastases. J. Immunol. 156: 238-245.
102. Schena M, Shalon D, Davis RW, Brown PO. (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: 467-470.
103. Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, Winlker J, Lockhart DJ, Morris MS, Fodor SP. (1996) Accessing genetic information with high-density DNA arrays. Science 274: 610-614.
104. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM. (1996) Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genet. 14: 457-460.